Literature DB >> 22379097

Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.

Nitin Verma1, Milena Dimitrova, Donald M Carter, Corey J Crevar, Ted M Ross, Hana Golding, Surender Khurana.   

Abstract

The H1N1 2009 influenza virus (H1N1pdm09) pandemic had several unexpected features, including low morbidity and mortality in older populations. We performed in-depth evaluation of antibody responses generated following H1N1pdm09 infection of naïve ferrets and of 130 humans ranging from the very young (0 to 9 years old) to the very old (70 to 89 years old). In addition to hemagglutination inhibition (HI) titers, we used H1N1pdm09 whole-genome-fragment phage display libraries (GFPDL) to evaluate the antibody repertoires against internal genes, hemagglutinin (HA), and neuraminidase (NA) and also measured antibody affinity for antigenic domains within HA. GFPDL analyses of H1N1pdm09-infected ferrets demonstrated gradual development of antibody repertoires with a focus on M1 and HA1 by day 21 postinfection. In humans, H1N1pdm09 infection in the elderly (>70 years old) induced antibodies with broader epitope recognition in both the internal genes and the HA1 receptor binding domain (RBD) than for the younger age groups (0 to 69 years). Importantly, post-H1N1 infection serum antibodies from the elderly demonstrated substantially higher avidity for recombinant HA1 (rHA1) (but not HA2) than those from younger subjects (50% versus <22% 7 M urea resistance, respectively) and lower antibody dissociation rates using surface plasmon resonance. This is the first study in humans that provides evidence for a qualitatively superior antibody response in the elderly following H1N1pdm09 infection, indicative of recall of long-term memory B cells or long-lived plasma cells. These findings may help explain the age-related morbidity and mortality pattern observed during the H1N1pdm09 pandemic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22379097      PMCID: PMC3347288          DOI: 10.1128/JVI.07085-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system.

Authors:  Shane Crotty; Rachael D Aubert; John Glidewell; Rafi Ahmed
Journal:  J Immunol Methods       Date:  2004-03       Impact factor: 2.303

2.  Revisiting the 1976 "swine flu" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice.

Authors:  Hang Xie; Xing Li; Jin Gao; Zhengshi Lin; Xianghong Jing; Ewan Plant; Olga Zoueva; Maryna C Eichelberger; Zhiping Ye
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

3.  Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains.

Authors:  Vernon J Lee; Joshua K Tay; Mark I C Chen; M C Phoon; M L Xie; Y Wu; Cynthia X X Lee; Jonathan Yap; K R Sakharkar; M K Sakharkar; Raymond T Lin; Lin Cui; Paul M Kelly; Yee Sin Leo; Yee Joo Tan; Vincent T K Chow
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

4.  Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus.

Authors:  Jonathan A McCullers; Lee-Ann Van De Velde; Kim J Allison; Kristen C Branum; Richard J Webby; Patricia M Flynn
Journal:  Clin Infect Dis       Date:  2010-06-01       Impact factor: 9.079

5.  Severe respiratory disease concurrent with the circulation of H1N1 influenza.

Authors:  Gerardo Chowell; Stefano M Bertozzi; M Arantxa Colchero; Hugo Lopez-Gatell; Celia Alpuche-Aranda; Mauricio Hernandez; Mark A Miller
Journal:  N Engl J Med       Date:  2009-06-29       Impact factor: 91.245

Review 6.  Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity.

Authors:  M K Slifka; R Ahmed
Journal:  Trends Microbiol       Date:  1996-10       Impact factor: 17.079

7.  Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Authors:  Surender Khurana; Wanida Chearwae; Flora Castellino; Jody Manischewitz; Lisa R King; Agnieszka Honorkiewicz; Michael T Rock; Kathryn M Edwards; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2010-01-20       Impact factor: 17.956

8.  Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.

Authors:  M Muramatsu; K Kinoshita; S Fagarasan; S Yamada; Y Shinkai; T Honjo
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

9.  Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza.

Authors:  Ted Ross; Shanta Zimmer; Don Burke; Corey Crevar; Donald Carter; James Stark; Brendan Giles; Richard Zimmerman; Stephen Ostroff; Bruce Lee
Journal:  PLoS Curr       Date:  2010-02-24

10.  Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

View more
  35 in total

1.  The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Bonnie B Blomberg
Journal:  Vaccine       Date:  2016-04-20       Impact factor: 3.641

2.  DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Authors:  Surender Khurana; Jian Wu; Milena Dimitrova; Lisa R King; Jody Manischewitz; Barney S Graham; Julie E Ledgerwood; Hana Golding
Journal:  J Infect Dis       Date:  2013-04-30       Impact factor: 5.226

3.  Diversifying Selection Analysis Predicts Antigenic Evolution of 2009 Pandemic H1N1 Influenza A Virus in Humans.

Authors:  Alexandra J Lee; Suman R Das; Wei Wang; Theresa Fitzgerald; Brett E Pickett; Brian D Aevermann; David J Topham; Ann R Falsey; Richard H Scheuermann
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

4.  Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy.

Authors:  Taia T Wang; Jad Maamary; Gene S Tan; Stylianos Bournazos; Carl W Davis; Florian Krammer; Sarah J Schlesinger; Peter Palese; Rafi Ahmed; Jeffrey V Ravetch
Journal:  Cell       Date:  2015-07-02       Impact factor: 41.582

5.  Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.

Authors:  Jad Maamary; Taia T Wang; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

6.  Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Bonnie B Blomberg
Journal:  Vaccine       Date:  2015-02-07       Impact factor: 3.641

7.  Age-Related Pathology Associated with H1N1 A/California/07/2009 Influenza Virus Infection.

Authors:  Stephanie J Bissel; Chalise E Carter; Guoji Wang; Scott K Johnson; Lauren P Lashua; Alyson A Kelvin; Clayton A Wiley; Elodie Ghedin; Ted M Ross
Journal:  Am J Pathol       Date:  2019-10-01       Impact factor: 4.307

Review 8.  Better immunity in later life: a position paper.

Authors:  Richard Faragher; Daniela Frasca; Edmond Remarque; Graham Pawelec
Journal:  Age (Dordr)       Date:  2014-02-16

9.  Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.

Authors:  Swati Verma; Milena Dimitrova; Ashok Munjal; Juan Fontana; Corey J Crevar; Donald M Carter; Ted M Ross; Surender Khurana; Hana Golding
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

10.  Antigenic Fingerprinting of Antibody Response in Humans following Exposure to Highly Pathogenic H7N7 Avian Influenza Virus: Evidence for Anti-PA-X Antibodies.

Authors:  Surender Khurana; Ka Yan Chung; Elizabeth M Coyle; Adam Meijer; Hana Golding
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.